| 10.58 0.4 (3.93%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.13 | 1-year : | 15.34 |
| Resists | First : | 11.25 | Second : | 13.13 |
| Pivot price | 10.31  |
|||
| Supports | First : | 8.53 |
Second : | 6.86 |
| MAs | MA(5) : | 10.31  |
MA(20) : | 9.98 |
| MA(100) : | 6.83 |
MA(250) : | 6.26 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 59.6 |
D(3) : | 59.8 |
| RSI | RSI(14): 63.3 |
|||
| 52-week | High : | 11.25 | Low : | 3.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMTX ] has closed below upper band by 33.3%. Bollinger Bands are 9.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.88 - 10.96 | 10.96 - 11.02 |
| Low: | 10.14 - 10.21 | 10.21 - 10.28 |
| Close: | 10.48 - 10.6 | 10.6 - 10.7 |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Mon, 27 Oct 2025
Immatics Appoints Amie Krause as Chief People Officer Amidst Commercial Transition - TipRanks
Mon, 27 Oct 2025
Immatics (NASDAQ: IMTX) names Amie Krause CPO to lead HR amid commercial-stage transition - Stock Titan
Mon, 27 Oct 2025
Immatics Appoints Amie Krause as Chief People Officer - GlobeNewswire
Fri, 24 Oct 2025
(IMTX) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Fri, 24 Oct 2025
Immatics N.V. (IMTX) Stock Analysis: Exploring a 40% Upside Potential in Cutting-Edge Cancer Therapies - DirectorsTalk Interviews
Fri, 10 Oct 2025
Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 122 (M) |
| Held by Insiders | 5.389e+007 (%) |
| Held by Institutions | 22.8 (%) |
| Shares Short | 3,580 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.83e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -57.5 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 121.5 % |
| Return on Equity (ttm) | -9.2 % |
| Qtrly Rev. Growth | 1.3013e+008 % |
| Gross Profit (p.s.) | -61.23 |
| Sales Per Share | -14.38 |
| EBITDA (p.s.) | -3.08525e+007 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -165 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.74 |
| Price to Cash Flow | 3.37 |
| Dividend | 0 |
| Forward Dividend | 4.56e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|